Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Taste Disorders 1Parasomnias 1Pain 1Olfaction Disorders 1Neoplasms 1Nausea 1Marijuana Abuse 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Cancer Pain 1Breast Neoplasms 1Anxiety Disorders 1Anorexia 1

Interventions

Fluorouracil 87Leucovorin 78Oxaliplatin 77Irinotecan 76Bevacizumab 50Cetuximab 42Capecitabine 42Panitumumab 17Folfox protocol 16Floxuridine 11Chemotherapy, Adjuvant 11regorafenib 10IFL protocol 10Nivolumab 9Drug Therapy 9trifluridine tipiracil drug combination 8Surgical Procedures, Operative 8Neoadjuvant Therapy 8sargramostim 7pembrolizumab 7XELOX 7Specimen Handling 7Biopsy 7Trastuzumab 6Radiotherapy 6Magnetic Resonance Spectroscopy 6HMPL-013 6tislelizumab 5encorafenib 5Trifluridine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colonic Neoplasms × Dronabinol × Clear all
NCT06731894 2025-12-05

Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

City of Hope Medical Center

Phase 2 Recruiting
120 enrolled
BreastGastrointestinal

Breast Neoplasms, Colonic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡